Study Stopped
Study never started
A Randomized Controlled Cost Study of Infuse BMP 2 vs Iliac Crest Autograft for Non Union of Long Bone Fractures
Infuse
2 other identifiers
interventional
N/A
1 country
1
Brief Summary
We are inviting individuals such as yourself, who have diaphyseal fracture (broken bone) with a non union to participate in this research study. A non-union is a lack of bone healing (bone growth where the break in the bone occurred) after 3 months after the operation. The diaphyseal is an area of a specific bone (usually near the middle) where the fracture occurred. The bones we are interested in are the clavicle (collar bone), tibia (lower leg), femur (upper leg), humerus (upper arm) and forearm (lower arm). Treatment goals for these types of fractures are to minimize later surgeries, to assist the healing process, and to decrease the time to healing. The ability of a patient with non-union (lack of bone healing after 3 months post operation) to return to the work force and to normal activities more quickly not only has a good financial impact on society (community), but also improves over-all physical and mental well-being of the patients. "Infuse" is a synthetic bone morphogenic protein which means it has the ability to help your bone to form and heal if inserted in the fracture site. "Infuse" may be the first commercially available product approved by Health Canada to accelerate the healing of long bone non-unions requiring surgical intervention. Although the safety and efficacy of Infuse has been demonstrated through numerous pre-clinical studies, further human clinical trial is needed to evaluate the safety and the power to produce effects of this product particularly with respect to non unions of long bones. The purpose of this study is to evaluate the safety and the power to produce effects of Infuse implanted during treatment of long bone non unions to reduce later surgeries required to augment the healing process and to accelerate the time to healing. Given this, the orthopaedic community has planned this study in order to scientifically establish the most effective treatment method to restore function after this type of injury.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Mar 2009
Longer than P75 for phase_4
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 26, 2009
CompletedStudy Start
First participant enrolled
March 1, 2009
CompletedFirst Posted
Study publicly available on registry
March 5, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2013
CompletedNovember 14, 2022
November 1, 2022
1 year
February 26, 2009
November 8, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
cost analysis based on length of hospital stay, allograft, blood products and costs associated with complications and/ or re-admission.
2 years
Secondary Outcomes (1)
Secondary efficacy end points will be the radiographic assessment of healing (RUST scale), the clinical assessment of weight-¬bearing status at 6 months post treatment, and the incidence of additional surgical/medical interventions to promote healing.
2 years
Study Arms (2)
1 Infuse
ACTIVE COMPARATORThe patient will receive BMP 2 with allograft
2 Iliac crest autograft
ACTIVE COMPARATORAutograft from Patients Iliac Crest and allograft
Interventions
"Infuse" is a synthetic bone morphogenic protein which means it has the ability to help your bone to form and heal if inserted in the fracture site. "Infuse" may be the first commercially available product approved by Health Canada to accelerate the healing of long bone non-unions requiring surgical intervention.
A piece of the patients iliac crest bone is take and mixed with bone from a bone bank to supplement the bone loss in the fracture
Eligibility Criteria
You may qualify if:
- Patients must meet all of the following criteria to be eligible for entry into the study:
- a) Patients must require open surgical treatment of non-union of a diaphyseal fracture of the tibia, humerus, femur, radius or ulna sustained secondary to trauma.
- c) Patients must be candidates for surgical treatment with an intramedullary nail or locked or unlocked plate.
- d) Patients must have a fracture of the diaphysis as defined for that specific bone.
- e) Patients must show radiographic evidence of skeletal maturity (closed epiphyseal plates).
You may not qualify if:
- Patients with any of the following criteria, are not eligible for entry into the study:
- Patients requiring mechanical fixation other than Intramedullary nailing or plating (i.e. no external fixation)
- Patients with fractures that fall outside the diaphysis defined for the specific bone in question, i.e. no metaphyseal fractures.
- Patients with segmental circumferential bone loss \>4cm.
- Patients whose fractures are the result of a tumour
- Patients with known metabolic bone disease (other than osteoporosis) which would negatively impact on the bone healing process.
- Patients with known sensitivity to collagen.
- Patients who are pregnant or breastfeeding at the time of study enrolment.
- Patients currently being treated with radiation, chemotherapy, immunosuppression, or steroid therapy.
- Patients receiving any other investigational drug or treatment.
- Patients who have other injuries or conditions such as they are unable to communicate or consent
- m)Patients with known breast or prostate cancer
- f) Patients must be able and willing to provide informed consent, to complete study assessments, and to be followed for the period of the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ross Leightonlead
- Canadian Orthopaedic Trauma Societycollaborator
Study Sites (1)
Halifax Infirmary
Halifax, Nova Scotia, B3h 1V7, Canada
Study Officials
- PRINCIPAL INVESTIGATOR
Ross K Leighton, MD
CDHA
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Orthopedic Surgeon
Study Record Dates
First Submitted
February 26, 2009
First Posted
March 5, 2009
Study Start
March 1, 2009
Primary Completion
March 1, 2010
Study Completion
March 1, 2013
Last Updated
November 14, 2022
Record last verified: 2022-11